Autolus Therapeutics Stock Alpha and Beta Analysis
| AUTL Stock | USD 1.91 0.04 2.05% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Autolus Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Autolus Therapeutics over a specified time horizon. Remember, high Autolus Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Autolus Therapeutics' market risk premium analysis include:
Beta 2.42 | Alpha 0.26 | Risk 5.02 | Sharpe Ratio 0.0713 | Expected Return 0.36 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Autolus Therapeutics Backtesting, Autolus Therapeutics Valuation, Autolus Therapeutics Correlation, Autolus Therapeutics Hype Analysis, Autolus Therapeutics Volatility, Autolus Therapeutics History and analyze Autolus Therapeutics Performance. Autolus Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Autolus Therapeutics market risk premium is the additional return an investor will receive from holding Autolus Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Autolus Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Autolus Therapeutics' performance over market.| α | 0.26 | β | 2.42 |
Autolus Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Autolus Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Autolus Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Autolus Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Autolus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Autolus Therapeutics shares will generate the highest return on investment. By understating and applying Autolus Therapeutics stock market price indicators, traders can identify Autolus Therapeutics position entry and exit signals to maximize returns.
Autolus Therapeutics Return and Market Media
The median price of Autolus Therapeutics for the period between Sat, Oct 11, 2025 and Fri, Jan 9, 2026 is 1.56 with a coefficient of variation of 12.43. The daily time series for the period is distributed with a sample standard deviation of 0.19, arithmetic mean of 1.56, and mean deviation of 0.15. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Longevity Biotech Surges as 72.6B Market Forecast Sparks Investment Rush - The Globe and Mail | 10/16/2025 |
2 | Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates - TradingView | 11/10/2025 |
3 | Should I buy Autolus Therapeutics plc stock before earnings season - July 2025 Decliners Daily Entry Point Alerts - newser.com | 11/18/2025 |
4 | Is Autolus Therapeutics PLC One of the Fastest-Growing Penny Stocks to Buy Now | 11/24/2025 |
5 | NICE Recommends AUCATZYL as a Treatment Option for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia | 11/25/2025 |
6 | Autolus Therapeutics Appoints Ryan Richardson to Board - TipRanks | 12/02/2025 |
7 | Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Soci... | 12/08/2025 |
8 | Wells Fargo Maintains Autolus Therapeutics With Buy Rating, Maintains Target Price 5 - | 12/09/2025 |
9 | How Autolus Therapeutics plc stock valuation compares with sector - 2025 Investor Takeaways Expert Curated Trade Setup Alerts - | 12/19/2025 |
10 | Aug Shorts Can Autolus Therapeutics plc Common Stock 6A3A stock expand revenue streams - July 2025 Fed Impact Free Reliable Trade Execution Plans - moha.gov.vn | 01/05/2026 |
11 | Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL on the Cellares Cell ShuttlePlatform | 01/06/2026 |
About Autolus Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Autolus or other stocks. Alpha measures the amount that position in Autolus Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Days Sales Outstanding | 225.06 | 1.7K | 2.0K | 1.9K | PTB Ratio | 10.05 | 1.4 | 1.61 | 1.53 |
Autolus Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Autolus Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Autolus Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Autolus Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Autolus Therapeutics. Please utilize our Beneish M Score to check the likelihood of Autolus Therapeutics' management manipulating its earnings.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Autolus Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Autolus Therapeutics Backtesting, Autolus Therapeutics Valuation, Autolus Therapeutics Correlation, Autolus Therapeutics Hype Analysis, Autolus Therapeutics Volatility, Autolus Therapeutics History and analyze Autolus Therapeutics Performance. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Autolus Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.